Developer docs
API playgroundTry for free, no card

Search company profiles

CarbGeM

Full company profile

uuid000osvl

Namestring
CarbGeM
Legal namestring
カーブジェン株式会社 (CarbGeM Inc.)
Websiteurl
carbgem.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

CarbGeM Inc. is a Tokyo-based AI and biotechnology company founded in March 2021 that develops AI-powered tools for clinical microbiology and life sciences research. The company's core products include BiTTE-Urine, a Class II Software as a Medical Device (SaMD) approved in Japan (December 2024) that estimates bacterial species from Gram-stained images with ~95% accuracy across 7 categories in approximately 10 seconds; BiTTE-iE, a research-use version distributed globally via app stores in 170+ countries; PoCGS automated Gram staining devices (Class I medical device and research-use variants); and the Bacterial Growth Monitor (BGM) using proprietary 2D TFT sensor technology for real-time quantitative microbial growth analysis at 5-minute intervals.

The company's technology foundation is the CarbConnect cloud-based AI platform, which combines proprietary deep learning models (CNN-based) for image analysis with a no-code AI Studio for model building, an enterprise tier for organizations with API integration capabilities, and a Community forum for expert knowledge sharing. The platform serves hospitals, clinical microbiology departments, academic researchers, pharmaceutical companies, and veterinary diagnostic laboratories across Japan, India, Southeast Asia, the Middle East, the US, and Europe.

CarbGeM generates revenue through multiple streams: SaaS subscriptions for CarbConnect (¥30,000/month basic tier), mobile app sales for BiTTE-iE, medical device sales for PoCGS-Pro and BiTTE-Urine (via NexxGen as manufacturing/distribution partner), professional services for the AI for Science Accompaniment Support offering, BGM service revenue for research collaborations, and licensing for the BiTTE-Urine SaMD. The company is led by CEO Masakazu Nakajima and co-founder Mac Taketani, with strategic partnerships including DSS Imagetech for India market entry, MEJ/JETRO/JICA for government-backed international expansion, and academic collaborations with NCGM, Kobe University, University of Tokyo, Keio University, Nagasaki Medical Center, Kameda Medical Center, and international institutions.

Short descriptiontext

CarbGeM is a Tokyo-based AI/biotech company developing SaMD-approved bacterial species estimation software, automated Gram staining devices, and a cloud AI image analysis platform (CarbConnect) serving hospitals, academic researchers, and life sciences institutions across global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShibuya, Japan
HQ citystring
Shibuya
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI microbiology diagnostics, bacterial image analysis, antimicrobial resistance software, clinical AI platform, Gram stain analysis
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
AI-powered clinical microbiology diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1SaaS Subscriptions (CarbConnect)
TypeSubscription Recurring
Description

Cloud-based AI image analysis platform offered as monthly or annual subscription. Basic plan for small teams starting at ¥30,000/month. Organization plans for enterprise deployment.

carbgem.com
2Mobile App Downloads/Subscriptions (BiTTE-iE)
TypeSubscription Recurring
Description

Research-use AI software available via App Store and Google Play in approximately 170 countries. Revenue from app sales or subscriptions.

carbgem.com
3Medical Device Sales (PoCGS-Pro)
TypeHardware Sales
Description

Automated Gram staining device classified as Class I general medical device. Direct sales to healthcare facilities for point-of-care testing.

carbgem.com
4BGM Service Revenue
TypeProfessional Services
Description

Bacterial Growth Monitor service providing device lending plus analytical support from CarbGeM's team. Applied in research collaborations and contract studies.

carbgem.com
5AI Implementation Services
TypeProfessional Services
Description

AI for Science accompanying support services with compute resource vouchers starting at ¥100,000. Includes consulting for regulatory compliance and social implementation.

carbgem.com
6Licensing (BiTTE-Urine)
TypeLicensing Royalties
Description

Class II SaMD approved software with manufacturing/sales through NexxGen Inc. Tokyo Data Lab. Licensed distribution model.

carbgem.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details3 tiers
1CarbConnect Basic Plan - ¥30,000/month for small teams and research groups
ModelSubscriptionBilling cadenceMonthly
Notes

Basic plan at ¥30,000/month (tax included). Cloud-based SaaS with 14-day free trial. Organization plans with custom pricing for universities, clinical labs, and enterprise R&D.

carbgem.com
2AI for Science Compute Voucher - Starting at ¥100,000
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Compute resource vouchers from ¥100,000 for life science AI implementation. Additional plans available through individual consultation.

carbgem.com
3BiTTE-Urine - Inquiry-based pricing for medical facility procurement
ModelSubscriptionBilling cadenceAnnual
Notes

Medical device (Class II) pricing through contact inquiry. Distribution via NexxGen Inc. as manufacturing/sales partner.

carbgem.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 5 records shown
1CarbConnect®
Description

Cloud-based AI image analysis platform for life sciences, enabling secure image storage, real-time communication, and AI model development.

carbgem.com
+4 more records
Core offering1 text field

CarbGeM develops and sells AI-powered image analysis software and SaaS platforms for microbiology and infectious disease diagnostics. Its flagship BiTTE-Urine is a Japan-approved Class II SaMD that classifies bacteria from Gram-stained images in about 10 seconds with 95% accuracy across 7 categories. The CarbConnect cloud platform enables no-code AI model building, enterprise deployment, and a professional community for life sciences, complemented by automated Gram staining devices (PoCGS) and a proprietary Bacterial Growth Monitor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BiTTE-Urine achieves 95% accuracy in 7-category bacterial classification compared to 83% accuracy for specialist medical professionals
+4 more records
Product overview1 text field

CarbGeM is a technology company offering a unified platform-plus-modules portfolio centered on CarbConnect®, a cloud-based AI image analysis platform for life sciences. The core product family includes BiTTE®-Urine (Class II SaMD for bacterial species estimation) and BiTTE®-iE (RUO version), paired with PoCGS® automated Gram staining devices (PoCGS®-Pro medical device and PoCGS®-iE for research). CarbConnect® serves as the central platform with modular add-ons: AI Studio for no-code model building, Community for expert collaboration, for Organizations enterprise tier, and Community Applications for global AI model integration. Supporting products include BGM for microbial growth monitoring, Pick Colony 1.0, ZOI Pro/VET, Nugent Score AI, and BM Smear AI 1.0. The portfolio addresses infectious disease diagnostics, antimicrobial resistance, research efficiency, and quality control automation.

Product and service4 records
1BiTTE-Urine
CategoryAI Clinical Diagnostics Software
Description

Class II SaMD-approved AI software that analyzes Gram-stained microscopy images via smartphone camera to estimate bacterial species causing urinary tract infections and suggest appropriate antimicrobial candidates based on antibiogram data, achieving 95% accuracy across 7 bacterial morphology categories in approximately 10 seconds.

2BiTTE-iE
CategoryResearch-use AI Software
Description

Research-use-only AI software for microbial estimation from Gram-stained images with three-level classification (morphology, species, intermediate). Available globally via mobile app in approximately 170 countries.

3PoCGS-Pro
CategoryAutomated Medical Device
Description

Class I medical device automated Gram staining system that completes fixation to staining in approximately 5 minutes with customizable protocols for reagent application, decolorizing, and rinsing settings.

4PoCGS-iE
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-13
Description

Strategic MOU signed to expand AI life science solutions in India. Leverages DSS's development, sales, and service infrastructure in microscopy and digital imaging. Aims to deploy CarbGeM's AI technologies across hospitals, laboratories, and research institutions throughout India to address antimicrobial resistance and healthcare disparities.

2Japan International Cooperation Agency (JICA)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-02-18
Description

Government organization providing support for CarbGeM's international expansion initiatives. Part of network supporting Japanese companies' global market entry.

carbgem.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-08-25
Description

METI program administrator supporting CarbGeM's international expansion. Facilitating participation in overseas exhibitions, trade missions, and market entry programs for healthcare DX solutions.

4Kobe Biomedical Innovation Cluster
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-05-30
Description

One of Japan's largest biomedical research clusters. CarbGeM exhibits through Kobe cluster booth at international medical fairs (MEDICAL FAIR THAILAND) to showcase Japanese healthcare innovations.

carbgem.com
5Sōi Ika Gakkai Holdings / Sōi Ika Kenkyū (Soi Medical Research)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

Joint development project on image AI technology for depression diagnosis drug development. Collaborative research combining CarbGeM's AI image analysis capabilities with medical research expertise.

carbgem.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-28
Description

Joint research collaboration on Bacterial Growth Monitor technology. Research成果 published in mBio journal demonstrating AI monitoring of Actinoplanes missouriensis growth dynamics. Co-authored publication on sortase SrtE and cell wall proteins in bacterial morphogenesis.

7NexxGen Inc. Tokyo Data Lab
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-12-16
Description

Manufacturing and sales partner for BiTTE-Urine SaMD. NexxGen serves as authorized manufacturing/distribution entity for the Class II approved medical device (approval number 30600BZX00247000).

carbgem.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-06
Description

Joint research collaboration in phage therapy field. Utilizing Bacterial Growth Monitor for phage efficacy evaluation and antimicrobial applications development.

9Swiss University of Zurich
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

Research collaboration on bacterial persistence mechanisms. Joint studies using Bacterial Growth Monitor technology for persister cell analysis and mechanism research.

carbgem.com
10Keio University School of Medicine
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Joint research collaboration on AI-powered diagnostic support solutions. Part of CarbGeM's portfolio of 20+ AI implementation projects in life sciences and healthcare domain.

carbgem.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-28
Description

Clinical research collaboration on AI-powered diagnostic solutions for infectious disease testing. Part of CarbGeM's academic partnership network for validation studies.

12Kobe University (Research Center for Urban Safety and Security)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

Joint R&D on compact automated Gram staining device PoCGS. Clinical study published in Diagnostics journal demonstrating 100% concordance with skilled technician manual staining. Continued collaboration on PoCGS development and enhancement.

carbgem.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-16
Description

Collaboration in bacterial infection disease using image recognition AI. Dr. Koichiro Shinozaki, assistant professor at Northwell Health (New York state's largest healthcare provider), appointed as clinical advisor.

14National Center for Global Health and Medicine / National Health Crisis Management Research Institute (JIHS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Long-standing joint research partnership for development of BiTTE-Urine SaMD. Co-developed patent for bacterial species estimation and antibiotic selection system. Clinical validation studies and non-inferiority trials conducted at NCGM and collaborating institutions.

carbgem.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Japan-headquartered clinical lab equipment leader with hematology, urinalysis, and emerging microbiology/AI workflows. Comparable as a fellow Japanese clinical diagnostics player with hospital relationships that could complement or compete with CarbGeM's BiTTE-Urine deployment.

TypeDirect peer
Description

Global leader in clinical microbiology with automated ID/AST systems (VITEK) and extensive Gram stain workflow. Directly comparable because both compete in bacterial identification and antimicrobial susceptibility, the core market CarbGeM targets with BiTTE-Urine and ZOI Pro.

TypeDirect peer
Description

Develops rapid AST/ID systems (e.g., Pheno) using automated microscopy and AI to shorten time-to-result for bloodstream infections. Directly comparable as a focused AI/microbiology player targeting antimicrobial resistance, a key end-market for CarbGeM's BiTTE suite.

TypeBroad incumbent
Description

Large medical device incumbent offering BD MAX, BD Phoenix, and microbiology lab automation. Comparable because BD owns the customer relationships and workflow that CarbGeM's SaaS and AI seek to augment, representing both a potential partner and competitor.

5Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Major clinical lab equipment provider (DxH hematology analyzers, microbiology automation). Comparable as a broad incumbent whose installed base in hospital labs is the channel CarbGeM targets with CarbConnect and BiTTE-Urine integrations.

TypeRegional player
Description

Japanese leader in photonic sensors and imaging components. Comparable because Hamamatsu supplies imaging/sensor technology for medical and life science applications — adjacent to CarbGeM's 2D TFT sensor-based BGM and microscopy-image AI workflow.

TypeEmerging player
Description

Small-cap company developing rapid molecular diagnostics for sepsis and bacterial infections. Comparable as a focused emerging microbiology diagnostics player addressing similar clinical use cases (rapid bacterial ID) with a smaller commercial footprint than incumbents.

TypeBroad incumbent
Description

AI-powered digital pathology company offering diagnostic and research pathology AI. Comparable as a pathology/microscopy AI vendor demonstrating the commercial trajectory AI-image-analysis companies can achieve in adjacent clinical imaging domains.

TypeBroad incumbent
Description

Leading clinical AI imaging company with FDA-cleared algorithms deployed across hospital radiology workflows. Comparable as a benchmark for the SaMD go-to-market motion CarbGeM must execute to convert BiTTE-Urine approval into hospital-wide adoption.

TypeOthers
Description

SaaS platform for life sciences R&D (electronic lab notebooks, molecular biology workflows). Comparable because CarbConnect and CarbConnect AI Studio target the same life-sciences R&D buyer persona with cloud-based AI tooling, though Benchling focuses on data infrastructure rather than imaging AI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CarbGeM

AI-powered clinical microbiology diagnosticscarbgem.com

CarbGeM is a Tokyo-based AI/biotech company developing SaMD-approved bacterial species estimation software, automated Gram staining devices, and a cloud AI image analysis platform (CarbConnect) serving hospitals, academic researchers, and life sciences institutions across global markets.

What CarbGeM does

CarbGeM Inc. is a Tokyo-based AI and biotechnology company founded in March 2021 that develops AI-powered tools for clinical microbiology and life sciences research. The company's core products include BiTTE-Urine, a Class II Software as a Medical Device (SaMD) approved in Japan (December 2024) that estimates bacterial species from Gram-stained images with ~95% accuracy across 7 categories in approximately 10 seconds; BiTTE-iE, a research-use version distributed globally via app stores in 170+ countries; PoCGS automated Gram staining devices (Class I medical device and research-use variants); and the Bacterial Growth Monitor (BGM) using proprietary 2D TFT sensor technology for real-time quantitative microbial growth analysis at 5-minute intervals.

The company's technology foundation is the CarbConnect cloud-based AI platform, which combines proprietary deep learning models (CNN-based) for image analysis with a no-code AI Studio for model building, an enterprise tier for organizations with API integration capabilities, and a Community forum for expert knowledge sharing. The platform serves hospitals, clinical microbiology departments, academic researchers, pharmaceutical companies, and veterinary diagnostic laboratories across Japan, India, Southeast Asia, the Middle East, the US, and Europe.

CarbGeM generates revenue through multiple streams: SaaS subscriptions for CarbConnect (¥30,000/month basic tier), mobile app sales for BiTTE-iE, medical device sales for PoCGS-Pro and BiTTE-Urine (via NexxGen as manufacturing/distribution partner), professional services for the AI for Science Accompaniment Support offering, BGM service revenue for research collaborations, and licensing for the BiTTE-Urine SaMD. The company is led by CEO Masakazu Nakajima and co-founder Mac Taketani, with strategic partnerships including DSS Imagetech for India market entry, MEJ/JETRO/JICA for government-backed international expansion, and academic collaborations with NCGM, Kobe University, University of Tokyo, Keio University, Nagasaki Medical Center, Kameda Medical Center, and international institutions.

CarbGeM firmographics

Firmographics
Name
CarbGeM
Legal name
カーブジェン株式会社 (CarbGeM Inc.)
Website
https://carbgem.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
CarbGeM is a Tokyo-based AI/biotech company developing SaMD-approved bacterial species estimation software, automated Gram staining devices, and a cloud AI image analysis platform (CarbConnect) serving hospitals, academic researchers, and life sciences institutions across global markets.
Ownership category
akta.pro rank

CarbGeM industry classification

Industry
Product category
AI-powered clinical microbiology diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI microbiology diagnostics
  • Bacterial image analysis
  • Antimicrobial resistance software
  • Clinical AI platform
  • Gram stain analysis

Where CarbGeM is headquartered

Location

Headquarters

HQ city
Shibuya
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

CarbGeM business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. SaaS Subscriptions (CarbConnect): Cloud-based AI image analysis platform offered as monthly or annual subscription. Basic plan for small teams starting at ¥30,000/month. Organization plans for enterprise deployment.
  2. Mobile App Downloads/Subscriptions (BiTTE-iE): Research-use AI software available via App Store and Google Play in approximately 170 countries. Revenue from app sales or subscriptions.
  3. Medical Device Sales (PoCGS-Pro): Automated Gram staining device classified as Class I general medical device. Direct sales to healthcare facilities for point-of-care testing.
  4. BGM Service Revenue: Bacterial Growth Monitor service providing device lending plus analytical support from CarbGeM's team. Applied in research collaborations and contract studies.
  5. AI Implementation Services: AI for Science accompanying support services with compute resource vouchers starting at ¥100,000. Includes consulting for regulatory compliance and social implementation.
  6. Licensing (BiTTE-Urine): Class II SaMD approved software with manufacturing/sales through NexxGen Inc. Tokyo Data Lab. Licensed distribution model.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCarbConnect Basic Plan - ¥30,000/month for small teams and research groups
Usage-basedPay-as-you-goAI for Science Compute Voucher - Starting at ¥100,000
SubscriptionAnnualBiTTE-Urine - Inquiry-based pricing for medical facility procurement

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

CarbGeM product offering

Product offering

Core offering

CarbGeM develops and sells AI-powered image analysis software and SaaS platforms for microbiology and infectious disease diagnostics. Its flagship BiTTE-Urine is a Japan-approved Class II SaMD that classifies bacteria from Gram-stained images in about 10 seconds with 95% accuracy across 7 categories. The CarbConnect cloud platform enables no-code AI model building, enterprise deployment, and a professional community for life sciences, complemented by automated Gram staining devices (PoCGS) and a proprietary Bacterial Growth Monitor.

Product overview

CarbGeM is a technology company offering a unified platform-plus-modules portfolio centered on CarbConnect®, a cloud-based AI image analysis platform for life sciences. The core product family includes BiTTE®-Urine (Class II SaMD for bacterial species estimation) and BiTTE®-iE (RUO version), paired with PoCGS® automated Gram staining devices (PoCGS®-Pro medical device and PoCGS®-iE for research). CarbConnect® serves as the central platform with modular add-ons: AI Studio for no-code model building, Community for expert collaboration, for Organizations enterprise tier, and Community Applications for global AI model integration. Supporting products include BGM for microbial growth monitoring, Pick Colony 1.0, ZOI Pro/VET, Nugent Score AI, and BM Smear AI 1.0. The portfolio addresses infectious disease diagnostics, antimicrobial resistance, research efficiency, and quality control automation.

Differentiator

Problem solved

Functional benefit

Brands

  • CarbConnect®: Cloud-based AI image analysis platform for life sciences, enabling secure image storage, real-time communication, and AI model development.
  • BiTTE®
  • PoCGS®
  • BGM (Bacterial Growth Monitor)
  • カーブジェン+ (CarbGeM+)

Products and services

  • BiTTE-Urine Class II SaMD-approved AI software that analyzes Gram-stained microscopy images via smartphone camera to estimate bacterial species causing urinary tract infections and suggest appropriate antimicrobial candidates based on antibiogram data, achieving 95% accuracy across 7 bacterial morphology categories in approximately 10 seconds.
  • BiTTE-iE Research-use-only AI software for microbial estimation from Gram-stained images with three-level classification (morphology, species, intermediate). Available globally via mobile app in approximately 170 countries.
  • PoCGS-Pro Class I medical device automated Gram staining system that completes fixation to staining in approximately 5 minutes with customizable protocols for reagent application, decolorizing, and rinsing settings.
  • PoCGS-iE

Quantifiable outcome

  • BiTTE-Urine achieves 95% accuracy in 7-category bacterial classification compared to 83% accuracy for specialist medical professionals
  • +4 more outcomes

Companies that use CarbGeM

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles5 records

CarbGeM technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature6 records

CarbGeM partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • DSS Imagetech Pvt. Ltd.coreChannel Partner/ Reseller/ Distributor · 13 March 2026Strategic MOU signed to expand AI life science solutions in India. Leverages DSS's development, sales, and service infrastructure in microscopy and digital imaging. Aims to deploy CarbGeM's AI technologies across hospitals, laboratories, and research institutions throughout India to address antimicrobial resistance and healthcare disparities.
  • Japan International Cooperation Agency (JICA)minorGTM or Marketing Partner · 18 February 2026Government organization providing support for CarbGeM's international expansion initiatives. Part of network supporting Japanese companies' global market entry.
  • Medical Excellence JAPAN (MEJ)coreGTM or Marketing Partner · 25 August 2025METI program administrator supporting CarbGeM's international expansion. Facilitating participation in overseas exhibitions, trade missions, and market entry programs for healthcare DX solutions.
  • Kobe Biomedical Innovation ClusterminorGTM or Marketing Partner · 30 May 2025One of Japan's largest biomedical research clusters. CarbGeM exhibits through Kobe cluster booth at international medical fairs (MEDICAL FAIR THAILAND) to showcase Japanese healthcare innovations.
  • Sōi Ika Gakkai Holdings / Sōi Ika Kenkyū (Soi Medical Research)minorStrategic or Co-development Partner · 7 May 2025Joint development project on image AI technology for depression diagnosis drug development. Collaborative research combining CarbGeM's AI image analysis capabilities with medical research expertise.
  • The University of Tokyo, Graduate School of Agricultural and Life Sciences (Ohnishi Laboratory)coreStrategic or Co-development Partner · 28 January 2025Joint research collaboration on Bacterial Growth Monitor technology. Research成果 published in mBio journal demonstrating AI monitoring of Actinoplanes missouriensis growth dynamics. Co-authored publication on sortase SrtE and cell wall proteins in bacterial morphogenesis.
  • NexxGen Inc. Tokyo Data LabcoreOEM/ Whitelabel/ Licensing Partner · 16 December 2024Manufacturing and sales partner for BiTTE-Urine SaMD. NexxGen serves as authorized manufacturing/distribution entity for the Class II approved medical device (approval number 30600BZX00247000).
  • Sentinel Environmental (USA)minorStrategic or Co-development Partner · 6 November 2024Joint research collaboration in phage therapy field. Utilizing Bacterial Growth Monitor for phage efficacy evaluation and antimicrobial applications development.
  • Swiss University of ZurichminorStrategic or Co-development Partner · 15 October 2024Research collaboration on bacterial persistence mechanisms. Joint studies using Bacterial Growth Monitor technology for persister cell analysis and mechanism research.
  • Keio University School of MedicineminorStrategic or Co-development Partner · 1 May 2024Joint research collaboration on AI-powered diagnostic support solutions. Part of CarbGeM's portfolio of 20+ AI implementation projects in life sciences and healthcare domain.
  • Nagasaki Medical CenterminorStrategic or Co-development Partner · 28 April 2024Clinical research collaboration on AI-powered diagnostic solutions for infectious disease testing. Part of CarbGeM's academic partnership network for validation studies.
  • Kobe University (Research Center for Urban Safety and Security)coreStrategic or Co-development Partner · 6 September 2022Joint R&D on compact automated Gram staining device PoCGS. Clinical study published in Diagnostics journal demonstrating 100% concordance with skilled technician manual staining. Continued collaboration on PoCGS development and enhancement.
  • Northwell Health (USA)minorStrategic or Co-development Partner · 16 February 2022Collaboration in bacterial infection disease using image recognition AI. Dr. Koichiro Shinozaki, assistant professor at Northwell Health (New York state's largest healthcare provider), appointed as clinical advisor.
  • National Center for Global Health and Medicine / National Health Crisis Management Research Institute (JIHS)coreStrategic or Co-development Partner · 1 April 2020Long-standing joint research partnership for development of BiTTE-Urine SaMD. Co-developed patent for bacterial species estimation and antibiotic selection system. Clinical validation studies and non-inferiority trials conducted at NCGM and collaborating institutions.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

CarbGeM competitors and assessment

Company assessment

Broad incumbents

  • Sysmex Corporation: Japan-headquartered clinical lab equipment leader with hematology, urinalysis, and emerging microbiology/AI workflows. Comparable as a fellow Japanese clinical diagnostics player with hospital relationships that could complement or compete with CarbGeM's BiTTE-Urine deployment.
  • Becton, Dickinson and Company (BD): Large medical device incumbent offering BD MAX, BD Phoenix, and microbiology lab automation. Comparable because BD owns the customer relationships and workflow that CarbGeM's SaaS and AI seek to augment, representing both a potential partner and competitor.
  • Beckman Coulter (Danaher): Major clinical lab equipment provider (DxH hematology analyzers, microbiology automation). Comparable as a broad incumbent whose installed base in hospital labs is the channel CarbGeM targets with CarbConnect and BiTTE-Urine integrations.
  • PathAI: AI-powered digital pathology company offering diagnostic and research pathology AI. Comparable as a pathology/microscopy AI vendor demonstrating the commercial trajectory AI-image-analysis companies can achieve in adjacent clinical imaging domains.
  • Aidoc: Leading clinical AI imaging company with FDA-cleared algorithms deployed across hospital radiology workflows. Comparable as a benchmark for the SaMD go-to-market motion CarbGeM must execute to convert BiTTE-Urine approval into hospital-wide adoption.

Direct peers

  • bioMérieux: Global leader in clinical microbiology with automated ID/AST systems (VITEK) and extensive Gram stain workflow. Directly comparable because both compete in bacterial identification and antimicrobial susceptibility, the core market CarbGeM targets with BiTTE-Urine and ZOI Pro.
  • Accelerate Diagnostics: Develops rapid AST/ID systems (e.g., Pheno) using automated microscopy and AI to shorten time-to-result for bloodstream infections. Directly comparable as a focused AI/microbiology player targeting antimicrobial resistance, a key end-market for CarbGeM's BiTTE suite.

Regional players

  • Hamamatsu Photonics: Japanese leader in photonic sensors and imaging components. Comparable because Hamamatsu supplies imaging/sensor technology for medical and life science applications — adjacent to CarbGeM's 2D TFT sensor-based BGM and microscopy-image AI workflow.

Emerging players

  • T2 Biosystems: Small-cap company developing rapid molecular diagnostics for sepsis and bacterial infections. Comparable as a focused emerging microbiology diagnostics player addressing similar clinical use cases (rapid bacterial ID) with a smaller commercial footprint than incumbents.

Others

  • Benchling: SaaS platform for life sciences R&D (electronic lab notebooks, molecular biology workflows). Comparable because CarbConnect and CarbConnect AI Studio target the same life-sciences R&D buyer persona with cloud-based AI tooling, though Benchling focuses on data infrastructure rather than imaging AI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CarbGeM social profiles

Digital presence

CarbGeM compliance and trust

Trust signal

Compliance1 record

CarbGeM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CarbGeM leadership team

Management profile

Number of profiles

Profiles1 record

CarbGeM subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CarbGeM funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CarbGeM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CarbGeM

What does CarbGeM do?

CarbGeM develops and sells AI-powered image analysis software and SaaS platforms for microbiology and infectious disease diagnostics. Its flagship BiTTE-Urine is a Japan-approved Class II SaMD that classifies bacteria from Gram-stained images in about 10 seconds with 95% accuracy across 7 categories. The CarbConnect cloud platform enables no-code AI model building, enterprise deployment, and a professional community for life sciences, complemented by automated Gram staining devices (PoCGS) and a proprietary Bacterial Growth Monitor.

Is CarbGeM a public or private company?

CarbGeM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CarbGeM founded?

CarbGeM was founded in 2021. It employs 11 to 50 people.

Where is CarbGeM based?

CarbGeM is headquartered in Shibuya, Japan, in the Asia region.

How does CarbGeM make money?

Six revenue lines are on record. SaaS Subscriptions (CarbConnect) is the primary driver. The others are mobile App Downloads/Subscriptions (BiTTE-iE), medical Device Sales (PoCGS-Pro), BGM Service Revenue, AI Implementation Services and licensing (BiTTE-Urine).

Who are CarbGeM's main competitors?

Broad incumbents on record are Sysmex Corporation, Becton, Dickinson and Company (BD), Beckman Coulter (Danaher), PathAI and Aidoc. Direct peers are bioMérieux and Accelerate Diagnostics. Hamamatsu Photonics is listed as a regional player. T2 Biosystems is listed as an emerging player. Benchling is listed as an others.

Does CarbGeM have an API?

Yes. CarbConnect® for Organizations supports API integration capabilities, enabling connections to proprietary AI systems. Organizations can integrate external AI tools and connect them through the platform's API infrastructure.

What industry is CarbGeM in?

CarbGeM's product category is AI-powered clinical microbiology diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals